MX351247B - Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. - Google Patents
Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.Info
- Publication number
- MX351247B MX351247B MX2012011371A MX2012011371A MX351247B MX 351247 B MX351247 B MX 351247B MX 2012011371 A MX2012011371 A MX 2012011371A MX 2012011371 A MX2012011371 A MX 2012011371A MX 351247 B MX351247 B MX 351247B
- Authority
- MX
- Mexico
- Prior art keywords
- fusions
- mycobacterium tuberculosis
- immunogenic compositions
- tuberculosis polypeptides
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente invención se refiere a una composición, caracterizada porque comprende un inmunoestimulante y una combinación de dos o más antígenos de Mycobacterium tuberculosis, en donde la combinación comprende un antígeno que tiene una secuencia que tiene por lo menos 90% de identidad (SEQ ID NO: 41) y un antígeno que tiene una secuencia que tiene por lo menos 905% de identidad a (SEQ ID NO: 46). Un polipéptido de fusión aislado, caracterizado porque comprende una combinación de dos o más antígenos de Mycobacterium tuberculosis covalentemente enlazados, en donde la combinación comprende un antígeno que tiene una secuencia que tiene por lo menos 90% de identidad y sus usos para estimular una respuesta inmune protectora.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91016907P | 2007-04-04 | 2007-04-04 | |
PCT/US2008/059500 WO2008124647A2 (en) | 2007-04-04 | 2008-04-04 | Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX351247B true MX351247B (es) | 2017-10-05 |
Family
ID=39620241
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012011371A MX351247B (es) | 2007-04-04 | 2008-04-04 | Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. |
MX2009010800A MX2009010800A (es) | 2007-04-04 | 2008-04-04 | Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009010800A MX2009010800A (es) | 2007-04-04 | 2008-04-04 | Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. |
Country Status (11)
Country | Link |
---|---|
US (4) | US8486414B2 (es) |
EP (2) | EP2136836B8 (es) |
JP (3) | JP5378350B2 (es) |
CN (2) | CN101687027B (es) |
BR (1) | BRPI0809926B8 (es) |
DK (1) | DK2136836T3 (es) |
ES (1) | ES2621211T3 (es) |
MX (2) | MX351247B (es) |
PL (1) | PL2136836T3 (es) |
WO (1) | WO2008124647A2 (es) |
ZA (1) | ZA200907316B (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2397855A3 (en) * | 2006-03-14 | 2012-03-14 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
MX351247B (es) | 2007-04-04 | 2017-10-05 | Infectious Disease Res Institute Star | Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. |
WO2011063263A2 (en) | 2009-11-20 | 2011-05-26 | Oregon Health & Science University | Methods for producing an immune response to tuberculosis |
US20130345079A1 (en) * | 2010-10-27 | 2013-12-26 | Infectious Disease Research Institute | Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity |
EP2573107A1 (en) * | 2011-09-21 | 2013-03-27 | Norwegian Institute of Public Health | A recombinant fusion protein |
WO2013090897A1 (en) * | 2011-12-15 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Using adaptive immunity to detect drug resistance |
CN102586139B (zh) * | 2012-01-20 | 2013-03-20 | 广东本科生物工程股份有限公司 | 一种高产ad/add的菌株及高效生产ad/add的方法 |
HUE044841T2 (hu) | 2012-02-07 | 2019-11-28 | Infectious Disease Res Inst | TLR4 agonistákat tartalmazó javított adjuváns készítmények és azok alkalmazási eljárásai |
EP3415919B1 (en) | 2012-02-07 | 2020-07-29 | Intuitive Biosciences Inc. | Mycobacterium tuberculosis specific peptides for detection of infection or immunization in non-human primates |
US10048561B2 (en) | 2013-02-21 | 2018-08-14 | View, Inc. | Control method for tintable windows |
WO2014009438A2 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterial antigen vaccine |
BR112015002483A2 (pt) * | 2012-08-03 | 2017-11-07 | Infectious Disease Res Inst | composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis |
CN102899334B (zh) * | 2012-10-29 | 2015-02-25 | 英诺特(唐山)生物技术有限公司 | 一种结核分枝杆菌重组蛋白质及其制备方法 |
AU2014232335C1 (en) | 2013-03-15 | 2016-09-01 | The Trustees Of The University Of Pennsylvania | Synthetic immunogens for prophylaxis or treatment of tuberculosis |
CN104237508B (zh) * | 2013-06-19 | 2015-12-02 | 华中农业大学 | 一种结核分枝杆菌的检测试剂盒及应用 |
CN104237509B (zh) * | 2013-06-19 | 2015-12-02 | 华中农业大学 | 一种结核分枝杆菌的检测试剂盒及应用 |
EP4176897A1 (en) * | 2013-06-25 | 2023-05-10 | International AIDS Vaccine Initiative, Inc. | Tuberculosis compositions and methods of using the same |
TWI654200B (zh) * | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
US9017698B2 (en) | 2013-09-25 | 2015-04-28 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9149522B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9149521B2 (en) | 2013-09-25 | 2015-10-06 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
US9504743B2 (en) | 2013-09-25 | 2016-11-29 | Sequoia Sciences, Inc | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
JP6249712B2 (ja) * | 2013-10-09 | 2017-12-20 | 公益財団法人ヒューマンサイエンス振興財団 | 非傍腫瘍性急性脳炎患者の予後診断装置の作動方法 |
CN103698531B (zh) * | 2013-11-25 | 2015-10-14 | 广东体必康生物科技有限公司 | Rv1860、Rv0173和/或Rv1812c蛋白在制备诊断活动性肺结核的产品中的用途 |
MX2016008640A (es) | 2013-12-31 | 2016-10-07 | Infectious Disease Res Inst | Formulaciones de vacuna de vial unico. |
CN106103471B (zh) | 2014-01-09 | 2020-01-07 | 特兰斯吉恩股份有限公司 | 异源寡聚分枝杆菌抗原的融合 |
KR101477795B1 (ko) | 2014-04-23 | 2015-01-02 | 건국대학교 산학협력단 | Adk 단백질을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물 |
EP3231439A4 (en) * | 2014-12-10 | 2018-01-24 | Konkuk University Glocal Industry-Academic Collaboration Foundation | Antibacterial composition containing adk protein as active ingredient, or composition for preventing or treating septicemia |
WO2016159741A1 (ko) * | 2015-04-03 | 2016-10-06 | 건국대학교 글로컬산학협력단 | Adk 단백질을 유효성분으로 포함하는 카바페넴 내성 그람음성균에 대한 항균용 조성물 |
CN106645733A (zh) * | 2015-07-16 | 2017-05-10 | 广东体必康生物科技有限公司 | 用于特异性检测结核分枝杆菌感染的蛋白 |
BR112018073676B1 (pt) | 2016-05-16 | 2023-10-03 | University Of Virginia Patent Foundation | Lipossomas peguilados e métodos de uso |
EP3458475B1 (en) | 2016-05-16 | 2022-07-27 | Access to Advanced Health Institute | Formulation containing tlr agonist and methods of use |
JP2019521095A (ja) * | 2016-05-21 | 2019-07-25 | インフェクシャス ディズィーズ リサーチ インスティチュート | 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法 |
KR102472026B1 (ko) | 2016-06-01 | 2022-11-30 | 액세스 투 어드밴스드 헬스 인스티튜트 | 사이징제를 함유하는 나노명반 입자 |
CN109890411A (zh) | 2016-06-16 | 2019-06-14 | 国际艾滋病疫苗行动组织公司 | 结核病组合物和治疗或预防结核病的方法 |
US11091775B2 (en) | 2016-06-22 | 2021-08-17 | Oregon Health And Science University | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
EP3555630B1 (en) | 2016-12-14 | 2023-05-31 | Becton, Dickinson and Company | Methods and compositions for obtaining a tuberculosis assessment in a subject |
CA3067224A1 (en) | 2017-06-15 | 2018-12-20 | Infectious Disease Research Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
CN107817228B (zh) * | 2017-06-30 | 2022-06-14 | 四川农业大学 | 对E.coli O157:H7免酶及免荧光标记的检测方法 |
CN111315406A (zh) | 2017-09-08 | 2020-06-19 | 传染病研究所 | 包括皂苷的脂质体调配物及其使用方法 |
EP3697806A4 (en) * | 2017-10-17 | 2021-10-27 | International AIDS Vaccine Initiative, Inc. | TUBERCULOSIS ANTIGEN CASSETTES |
WO2019126523A2 (en) * | 2017-12-22 | 2019-06-27 | Massachusetts Eye And Ear Infirmary | Comprehensive microbial panel for molecular diagnosis of eye infections |
WO2019210282A2 (en) * | 2018-04-26 | 2019-10-31 | Children's National Medical Center | Mycobacterial antigen compositions and methods of use |
CN108411030B (zh) * | 2018-05-25 | 2021-05-14 | 兰州大学 | 引物对及包含其的试剂盒、用途和检测蒺藜苜蓿生态型a17和r108的方法 |
CN108948175B (zh) * | 2018-07-23 | 2020-11-20 | 首都医科大学附属北京胸科医院 | 与人类蛋白smad2相互作用的结核蛋白及其应用 |
CN112770771A (zh) * | 2018-09-17 | 2021-05-07 | 丘拉提斯股份有限公司 | 包含干扰素基因刺激蛋白激动剂的免疫佐剂及疫苗组合物 |
KR102524577B1 (ko) * | 2019-04-22 | 2023-04-21 | 전남대학교산학협력단 | 플라젤린 융합 단백질 및 이의 용도 |
CN113784974A (zh) * | 2019-05-02 | 2021-12-10 | L基础有限公司 | 新型寡肽和包含该寡肽作为活性成分的用于预防或治疗癌症的药物组合物 |
JP2022532944A (ja) | 2019-05-25 | 2022-07-20 | アクセス ツー アドバンスト ヘルス インスティチュート | アジュバントワクチンエマルジョンを噴霧乾燥するための組成物および方法 |
GB201909953D0 (en) * | 2019-07-11 | 2019-08-28 | Sec Dep For Environment Food And Rural Affairs Acting Through The Animal And Plant Health Agency | Diagnostic reagents |
US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
CN111286551A (zh) * | 2020-01-04 | 2020-06-16 | 昆明理工大学 | 结核分枝杆菌的快速检测引物、试剂盒及其使用方法 |
GB2605538A (en) | 2020-03-23 | 2022-10-05 | Hdt Bio Corp | Compositions and methods for delivery of RNA |
CA3173408A1 (en) | 2020-12-23 | 2022-06-30 | Access To Advanced Health Institute | Solanesol vaccine adjuvants and methods of preparing same |
CN113121703B (zh) * | 2021-03-03 | 2023-04-25 | 上海晶诺生物科技有限公司 | 一种具有结核杆菌免疫原性的融合蛋白及其应用 |
CN114150006B (zh) * | 2021-11-29 | 2023-07-25 | 中国农业科学院植物保护研究所 | 一种可提高米尔贝霉素产量的基因簇、重组菌及其制备方法与应用 |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
CN116041454B (zh) * | 2022-12-07 | 2023-12-26 | 中国疾病预防控制中心传染病预防控制所 | 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因、应用 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US4761180A (en) | 1986-08-27 | 1988-08-02 | Hewlett-Packard Company | Dyes containing tetramethylammonium cation for ink-jet printing inks |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
DE69312487T2 (de) | 1992-05-18 | 1997-11-27 | Minnesota Mining & Mfg | Einrichtung zur transmucosalen wirkstoffabgabe |
ES2143716T3 (es) | 1992-06-25 | 2000-05-16 | Smithkline Beecham Biolog | Composicion de vacuna que contiene adyuvantes. |
US5359681A (en) | 1993-01-11 | 1994-10-25 | University Of Washington | Fiber optic sensor and methods and apparatus relating thereto |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
DE69535905D1 (de) | 1994-07-15 | 2009-02-26 | Coley Pharm Group Inc | Immunomodulatorische Oligonukleotide |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6355257B1 (en) | 1997-05-08 | 2002-03-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
EP1484405A1 (en) | 1997-11-10 | 2004-12-08 | Statens Serum Institut | Nucleic acid fragments and polypeptide fragments derived from M. Tuberculosis |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
US20020081579A1 (en) | 1998-02-13 | 2002-06-27 | Jane E. R. Potter | Method for the isolation of novel antigens |
TR200002938T2 (tr) | 1998-04-07 | 2001-02-21 | Corixa Corporation | Mikrobakteri tüberküloz antijenlerinin füzyon proteinleri ve bunların kullanımı |
WO1999052549A1 (en) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
AU773204C (en) | 1998-08-10 | 2005-05-19 | Antigenics Llc | Compositions of CPG and saponin adjuvants and methods thereof |
JP2003510370A (ja) * | 1999-10-07 | 2003-03-18 | コリクサ コーポレイション | Mycobacteriumtuberculosisの融合タンパク質 |
US7472098B2 (en) | 2000-02-14 | 2008-12-30 | Ubs Financial Services, Inc. | System and method for execution of trades made pursuant to stock option and purchase plans |
ES2374620T3 (es) | 2000-06-20 | 2012-02-20 | Corixa Corporation | Antígeno mtb32a de mycobacterium tuberculosis con el sitio activo inactivado y proteínas de fusión de los mismos. |
AU2003224313A1 (en) | 2002-04-27 | 2003-11-17 | The Secretary Of State For Environment, Food And Rural Affairs | Mycobacterial antigens and uses thereof |
EP1523331B1 (en) * | 2002-07-13 | 2013-02-27 | Statens Serum Institut | Therapeutic tb vaccine |
US8128941B2 (en) | 2004-08-26 | 2012-03-06 | Chembio Diagnostic Systems, Inc. | Assay for detecting tuberculosis in nonhuman primates |
WO2006026464A2 (en) * | 2004-08-27 | 2006-03-09 | Davidsen Kevin P | Handclapping aid |
EP1910409A2 (en) * | 2005-06-23 | 2008-04-16 | Statens Serum Institut | Tuberculosis vaccines comprising antigens expressed during the latent infection phase |
PL2484375T3 (pl) | 2006-09-26 | 2018-09-28 | Infectious Disease Research Institute | Kompozycja szczepionki zawierająca syntetyczny adiuwant |
MX351247B (es) | 2007-04-04 | 2017-10-05 | Infectious Disease Res Institute Star | Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. |
-
2008
- 2008-04-04 MX MX2012011371A patent/MX351247B/es unknown
- 2008-04-04 CN CN200880017215.7A patent/CN101687027B/zh active Active
- 2008-04-04 US US12/594,806 patent/US8486414B2/en active Active
- 2008-04-04 PL PL08745178T patent/PL2136836T3/pl unknown
- 2008-04-04 MX MX2009010800A patent/MX2009010800A/es active IP Right Grant
- 2008-04-04 ES ES08745178.7T patent/ES2621211T3/es active Active
- 2008-04-04 DK DK08745178.7T patent/DK2136836T3/en active
- 2008-04-04 EP EP08745178.7A patent/EP2136836B8/en active Active
- 2008-04-04 BR BRPI0809926A patent/BRPI0809926B8/pt active IP Right Grant
- 2008-04-04 EP EP16206308.5A patent/EP3199176B1/en active Active
- 2008-04-04 WO PCT/US2008/059500 patent/WO2008124647A2/en active Application Filing
- 2008-04-04 CN CN201410837977.9A patent/CN104815324A/zh active Pending
- 2008-04-04 JP JP2010502340A patent/JP5378350B2/ja active Active
-
2009
- 2009-10-19 ZA ZA2009/07316A patent/ZA200907316B/en unknown
-
2013
- 2013-03-08 US US13/791,511 patent/US9822152B2/en active Active
- 2013-09-25 JP JP2013198204A patent/JP5922074B2/ja active Active
-
2016
- 2016-02-05 JP JP2016020683A patent/JP2016145209A/ja active Pending
-
2017
- 2017-11-16 US US15/815,512 patent/US11091521B2/en active Active
-
2021
- 2021-07-06 US US17/367,812 patent/US11897922B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
BRPI0809926B1 (pt) | 2020-09-29 |
US9822152B2 (en) | 2017-11-21 |
ZA200907316B (en) | 2013-03-27 |
US20220017578A1 (en) | 2022-01-20 |
JP5378350B2 (ja) | 2013-12-25 |
EP2136836A2 (en) | 2009-12-30 |
MX2009010800A (es) | 2010-01-29 |
US11091521B2 (en) | 2021-08-17 |
JP2014058520A (ja) | 2014-04-03 |
JP5922074B2 (ja) | 2016-05-24 |
CN101687027A (zh) | 2010-03-31 |
ES2621211T3 (es) | 2017-07-03 |
BRPI0809926A2 (pt) | 2014-10-07 |
WO2008124647A2 (en) | 2008-10-16 |
EP3199176A1 (en) | 2017-08-02 |
DK2136836T3 (en) | 2017-04-10 |
US20100129391A1 (en) | 2010-05-27 |
US8486414B2 (en) | 2013-07-16 |
EP2136836B1 (en) | 2017-01-04 |
US11897922B2 (en) | 2024-02-13 |
EP3199176B1 (en) | 2020-02-19 |
EP2136836B8 (en) | 2017-04-12 |
CN101687027B (zh) | 2015-01-28 |
US20180170975A1 (en) | 2018-06-21 |
WO2008124647A3 (en) | 2009-04-02 |
JP2010524854A (ja) | 2010-07-22 |
CN104815324A (zh) | 2015-08-05 |
BRPI0809926B8 (pt) | 2021-05-25 |
JP2016145209A (ja) | 2016-08-12 |
US20130209500A1 (en) | 2013-08-15 |
PL2136836T3 (pl) | 2017-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009010800A (es) | Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. | |
SG158145A1 (en) | Vaccines against chlamydial infection | |
WO2006082406A3 (en) | Human antibodies and proteins | |
UA107329C2 (uk) | Туберкульозний білок rv2386c, композиція, що його містить, та застосування | |
EP1784639A4 (en) | PROCESS FOR PREPARING FREEZERTED BLOOD PLATES, FLUIDIZED BLOOD PLATES, COMPOSITIONS AND USE METHOD | |
MX2007003402A (es) | Composicion inmunogena para su uso en vacunacion contra estafilococos. | |
UA107330C2 (uk) | Туберкульозний білок rv3616c та його застосування | |
MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
MY158438A (en) | Antibodies against human angiopoietin 2 | |
UA107180C2 (uk) | Туберкульозний білок rv1753c, композиція, що його містить, та застосування | |
MX2010004482A (es) | Anticuerpos anti-proteina g vsr. | |
MX2009006760A (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas. | |
MX2009012950A (es) | ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS. | |
MXPA06010469A (es) | Proteina recombinante portadora de epitopos del virus de papiloma humano insertados en una proteina adenilato ciclasa o en un fragmento de ella y sus usos terapeuticos. | |
WO2010039224A3 (en) | Respiratory syncytial virus (rsv) sequences for protein expression and vaccines | |
DK2054431T3 (da) | Konformere af bakterielle adhæsiner | |
MX364623B (es) | Fragmentos mutantes de ospa y métodos y usos relacionados con estos. | |
MX2010005589A (es) | Composicion para el cuidado personal. | |
CL2007003190A1 (es) | Compuestos derivados de arilsulfonil-pirrolidinas; procedimiento de obtencion; composicion farmaceutica; y uso en la prevencion o tratamiento de enfermedades tales como psicosis, depresion, alzheimer, entre otras. | |
WO2016161415A3 (en) | Tnfrsf14/ hvem proteins and methods of use thereof | |
MX2016008989A (es) | Fragmentos mutantes de ospa y metodos y usos relacionados con estos. | |
WO2008040190A8 (en) | Small peptides for anti-angiogenesis and use thereof | |
MX2012004622A (es) | Adyuvante para vacunas, vacunas que lo comprenden y usos. | |
MX2007003624A (es) | Peptidos y derivados tipo peptido ligando alterado de la hsp60 y composiciones farmaceuticas. | |
MX2007011381A (es) | Composicion de espirulinas rica en principios activos, su proceso de obtencion y su utilizacion. |